Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $36
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $38 to $36.
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $38 to $36.